Published Date: 30/01/2011
Category: Drug Delivery & Devices
Research Report Decription
A comprehensive examination of trends and advances in the two major drug
delivery sectors
Unique sales forecasts to 2015 for key technology areas
Critical analyses of specialist developers driving the market onwards
The increasing number of new biological products, and the emergence of a
biosimilars market has focused the industry’s attention on the development of
novel and advanced drug delivery technologies which can deliver these new
targeted products. However, oral and parenteral drug administration still
dominates the market, and technical innovation is ensuring these tried and
tested routes of administration continue to offer more compelling and effective
methods of drug delivery.
The
global pharmaceutical industry generated revenues of over US$800 billion in
2009, growing at around 7% per annum. Oral
formulations accounted for almost 60% of prescriptions, with the top 10 oral
products accounting for nearly 10% of total global pharmaceutical sales. The
global market for oral drug delivery enhanced products (DDEPs) was estimated to
be worth around US$51 billion in 2009, accounting for nearly 60% of the market
share of the entire DDEP market; sustained-release formulations represented
over 95% of all oral DDEPs.Parenteral
drug delivery is the second largest segment of the market accounting for nearly
30% of the market share. It is presently valued at US$27 billion and is
expected to reach US$51 billion by 2015 driven primarily by the launch of new
biologics; the uptake of novel delivery platforms and the utilisation of
controlled-release systems.The report provides a detailed insight into the current and future market for oral
and parenteral drug delivery technology, and...
- Provides an overview of the marketplace, outlining current thinking on the
technologies being researched and employed
- Appraises currently available products which utilise advanced delivery
platforms
- Examines new product developments from major specialist drug delivery
companies, critically analysing their prospects
- Allows ready comparison on different technologies within a company’s
portfolio.
Use
this report to...
- Assess the strengths and weaknesses of competing products/technologies
in the context of specific delivery sectors and development companies
- Identify and review licensing and collaborative partners
- Understand the merits and applications of the main approaches being
researched.
- Quantify the commercial prospects for current and future products.
Key Questions Answered:
Volume I Oral Delivery Technology: This report answer key questions
- What % of the oral drug delivery market by value do emerging markets
account for?
- What is the current state of play with sustained, modified, chrono and
pulsatile release technologies?
- What are the leading products that utilise advanced oral delivery and in
what therapeutic areas are they most commonly applied?
- What research is being undertaken to develop novel drug delivery
technologies for cancer?
- Will oral delivery
technology ever crack the large molecule problem?
Volume II Parenteral Delivery Technology: This
report answers key questions
- What trends are driving the
parenteral delivery sector to double digit growth?
- Which sector of the market
is expected to grow by a CAGR of 15% to 2015?
- Which companies are
developing technologies for the delivery of poorly-soluble drugs?
- What is the current state
of play for auto injectors and insulin pumps for the treatment of diabetes?
- What clinical benefits are
there in the subcutaneous delivery of monoclonal antibodies?
Companies Mentioned:
Volume I Oral Delivery Technology Companies
Access Pharmaceuticals, Acura Pharmaceuticals, Akina, Alizyme, ALZA Corporation, BTG, Biovail Corporation, Camurus AB, Catalent Pharma Solutions, Cipher Pharmaceuticals, Cosmo Pharmaceuticals S.p.A, Depomed Technologies, Durect Coproration, Elan Corporation, Egalet Ltd, Elite PHarmaceuticals, Emisphere Technologies, Ethypharm SA, Eurand, Flamel Technologies, KV Pharmaceuticals, Labopharm, Lavipharm SA, Penwest Pharmaceuticals, SCLOR Pharma, Shire Plc, SykePharma, Watson pharmaceutcials.
Volume II Parenteral Delivery Technology Companies
Abraxis Biosciences, Access Pharmaceuticals, Alkermes, Antares Pharma, Becton Dickinson, Bespak Pharmaceuticals, BioGenerIX AG, Bioject Medical Technologies, Biophan Technologies, Camurus AB, CyDex Pharmaceuticals, Enzon Pharmaceuticals, Genzyme Corporation, Glide Pharmaceutical Technologies, Lipoxen, Mountain View Pharmaceuticals, Nektar Therapeutics, Novavax, OctoPlus N.V., Polytherics, pSivida Corporation, QLT, Starpharma Holdings, SurModics
Paper Highlights:
Volume
I Oral Delivery Technology
- During the last 30 years, considerable advances have been made in drug delivery
technologies, particularly in the field of controlled-release delivery.
However, there is an unremitting demand for products that achieve continuous
release of therapeutic agents over extended time periods. This has led to the
development of a multitude of drug delivery platforms mainly involving either
multi-particulate dosage forms (e.g. pellets contained in gelatine capsules) or
single-unit dosage forms (e.g. bilayer or multilayer tablets), and a variety of
release profiles.
- Currently-marketed oral DDEPs encompass several therapeutic categories
including cancer, cardiovascular, central nervous system, musculoskeletal,
metabolic diseases (diabetes) and respiratory conditions. Oral disintegrating
tablets (ODTs) or melts have evolved as an important delivery system for drugs
that treat medical conditions vulnerable to a sudden onset of symptoms such as
allergies, migraine, reflux disease and schizophrenia.In addition, oral DDEP
platforms have been utilised to reduce the abuse-resistance of opioids and to
prevent alcohol “dose dumping.”
- Oral DDEPs are widely used across the globe as patients migrate towards
convenient dosage formulations. Controlled-release tablets and capsules remain
the main formulation platform although orally disintegrating, nanoparticle and
combined technology formulations are expected to broaden applications in the
future. Oral DDEPs use a variety of mechanisms to modify the controlled delivery of the
molecule (drug) including: osmotic-driven drug release, degradation-driven
release, diffusion-controlled release or through a combination of delivery
platforms.
- Advanced oral DDEPs can be used to target release within specific
regions of the GI tract such as Alizyme’s Colal delivery system and Cosmo’s MMX
technology. In addition, companies have developed pulsatile-release platforms
that allow drug release to more closely follow circadian rhythms, such as BTG’s
Pulsincap.
- A vigorous research environment
Over 800 companies are currently involved in the development of oral drug
delivery technologies from large pharma to specialty delivering technologists.
This report identifies 29 of the top movers and shakers in the oral delivery
industry.
Volume
II - Parenteral Delivery Technology
- Over the last 50 years, considerable technological advances have been made in
the area of parenteral drug delivery to overcome the many limitations
associated with this route of delivery. This has led to the development of
sophisticated systems that allow drug targeting and the sustained or controlled
release of parenteral medicines. Over the next ten years more than 30 new
targeted-delivery products are expected to be commercially released and more
than 35 nano-enabled nucleic acid products could reach the market.
- Improvements in parenteral delivery devices such as pre-filled syringes, pens,
auto-injectors and needle-free devices continue to alleviate the burden of
self-administration and improve patient compliance. Meanwhile the explosion of
biological therapies provides additional challenges for drug delivery
specialists seeking to develop ways of improving on standard injections for
these products.
- Widening therapeutic uses for parenteral delivery.The development of new and approved agents for oncology, infectious disease,
endocrinology and inflammatory and immune-related diseases continues to fuel
the growth of injectable DDEPs. This market will be driven by the
identification of novel drug targets and the development of innovative
immunotherapeutics that address areas of high unmet clinical need, a segment
that has been historically poorly treated with oral therapeutics. Parenteral
DDEPs are widely used across the globe, but tend to be priced at a premium due
to the sophisticated delivery devices which often require administration from a
healthcare professional. Innovation from a vigorous research-based sector.
- Parenteral DDEPs apply to a variety of formulations and devices in which to
modify the delivery of small and large molecule drugs. Self-injection devices
include pen injectors, auto-injectors, needle-free injectors and nasal spray
devices while formulation-based technologies range from liposomes and
emulsions, PEGylation, microparticles and nanoparticles and dendrimers, either
used alone or in combination to optimise delivery and minimise off-target
toxicities.
- Over 250 companies are currently involved in the development of
parenteral drug delivery technologies from large pharma to specialty delivery
technologists, and this report analyses 24 of the leading players.
